Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2025-12-26 @ 2:09 AM
Study NCT ID:
NCT03403205
Status:
TERMINATED
Last Update Posted:
2024-06-17
First Post:
2017-12-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Belgium', 'Italy']}, 'conditionBrowseModule': {'meshes': [{'id': 'D006527', 'term': 'Hepatolenticular Degeneration'}], 'ancestors': [{'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D008664', 'term': 'Metal Metabolism, Inborn Errors'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C020809', 'term': 'tetrathiomolybdate'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@alexion.com', 'phone': '+1 855-752-2356', 'title': 'Alexion Pharmaceuticals Inc.', 'organization': 'Alexion Pharmaceuticals Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'For PEP participants: From Primary Evaluation Period Baseline up to Primary Evaluation Period Week 48/Early Termination; For OLE and WTX101-201 participants: From Extension Period Week 1 up to Extension Period Week 268/Early Termination', 'description': 'Safety analysis set included all participants who received at least 1 dose of randomized treatment.', 'eventGroups': [{'id': 'EG000', 'title': 'PEP Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks.', 'otherNumAtRisk': 104, 'deathsNumAtRisk': 104, 'otherNumAffected': 46, 'seriousNumAtRisk': 104, 'deathsNumAffected': 1, 'seriousNumAffected': 14}, {'id': 'EG001', 'title': 'PEP Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy for up to 48 weeks according to the local package label.', 'otherNumAtRisk': 56, 'deathsNumAtRisk': 56, 'otherNumAffected': 18, 'seriousNumAtRisk': 56, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG002', 'title': 'PEP Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks.', 'otherNumAtRisk': 33, 'deathsNumAtRisk': 33, 'otherNumAffected': 16, 'seriousNumAtRisk': 33, 'deathsNumAffected': 1, 'seriousNumAffected': 4}, {'id': 'EG003', 'title': 'PEP Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy for up to 48 weeks according to the local package label.', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 7, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'OLE Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) who completed the 48-week PEP of study WTX101-301 were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.', 'otherNumAtRisk': 89, 'deathsNumAtRisk': 89, 'otherNumAffected': 45, 'seriousNumAtRisk': 89, 'deathsNumAffected': 1, 'seriousNumAffected': 20}, {'id': 'EG005', 'title': 'OLE Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) who completed the 48-week PEP of study WTX101-301 were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.', 'otherNumAtRisk': 49, 'deathsNumAtRisk': 49, 'otherNumAffected': 32, 'seriousNumAtRisk': 49, 'deathsNumAffected': 0, 'seriousNumAffected': 10}, {'id': 'EG006', 'title': 'OLE Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.', 'otherNumAtRisk': 28, 'deathsNumAtRisk': 28, 'otherNumAffected': 10, 'seriousNumAtRisk': 28, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG007', 'title': 'OLE Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 4, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG008', 'title': 'Cohort 1: WTX101-201- ALXN1840', 'description': 'Participants who received ALXN1840 during Study WTX101-201 (NCT02273596) continued to receive ALXN1840 for up to 60 months.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 6, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG009', 'title': 'Cohort 2: WTX101-201- ALXN1840', 'description': 'Participants who received ALXN1840 during Study WTX101-201 (NCT02273596) continued to receive ALXN1840 for up to 60 months.', 'otherNumAtRisk': 11, 'deathsNumAtRisk': 11, 'otherNumAffected': 7, 'seriousNumAtRisk': 11, 'deathsNumAffected': 0, 'seriousNumAffected': 3}], 'otherEvents': [{'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 10, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 14, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 12, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 14, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 9, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 24, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 13, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 16, 'numAffected': 13}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 5, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 8, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 8, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 10, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 13, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 12, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 23, 'numAffected': 22}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 12, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 13, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}], 'seriousEvents': [{'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepato-lenticular degeneration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Varices oesophageal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertransaminasaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Liver disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Epididymitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urosepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Facial bones fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastrostomy tube site complication', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Intentional overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rib fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Bursitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Rhabdomyolysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatocellular carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lipoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Transitional cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Balance disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dystonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatic encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Neurological decompensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Device malfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Paranoia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Persistent depressive disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Suicidal ideation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Aspiration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pneumothorax spontaneous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pleural effusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Venous thrombosis limb', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Coronary artery occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Supraventricular tachyarrhythmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Mouth ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Unevaluable event', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acute hepatic failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cholecystitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatic failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Herpes simplex hepatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Retroperitoneal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Humerus fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Road traffic accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hepatic enzyme increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Malnutrition', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fracture malunion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Neuropathic arthropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Malignant melanoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Plasma cell myeloma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Transitional cell carcinoma recurrent', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Uterine leiomyoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dyskinesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Device dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Alcoholism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Mental disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Post-traumatic stress disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Ovarian cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Uterine cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Microcytic anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Umbilical hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Burns second degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Procedural pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Sports injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Upper limb fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Anal cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Neurological symptom', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Delusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Mania', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Panic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Suicide attempt', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Urethral stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 104, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 56, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 33, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 12, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.50', 'spread': '0.150', 'groupId': 'OG000', 'lowerLimit': '0.150'}, {'value': '0.87', 'spread': '0.204', 'groupId': 'OG001', 'lowerLimit': '0.204'}, {'value': '4.76', 'spread': '0.319', 'groupId': 'OG002', 'lowerLimit': '0.319'}, {'value': '0.96', 'spread': '0.487', 'groupId': 'OG003', 'lowerLimit': '0.487'}]}]}], 'analyses': [{'pValue': '< 0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.64', 'ciLowerLimit': '1.14', 'ciUpperLimit': '2.13', 'pValueComment': 'Test was performed at a significance level of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.254', 'groupDescription': 'Analysis was performed using ANCOVA model, which included treatment, cohort, and baseline value. Missing imputation was performed: 1) for intermediate missing, interpolation was used to fill out missing values. 2) For participants who die, baseline dNCC was carried forward from discontinuation to week 48. 3) For others, multiple imputation was used to impute missing dNCC assuming data were missing not at random.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '< 0.0001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.79', 'ciLowerLimit': '2.65', 'ciUpperLimit': '4.94', 'pValueComment': 'Test was performed at a significance level of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.584', 'groupDescription': 'Analysis was performed using ANCOVA model, which included treatment, cohort, and baseline value. Missing imputation was performed: 1) for intermediate missing, interpolation was used to fill out missing values. 2) For participants who die, baseline dNCC was carried forward from discontinuation to week 48. 3) For others, multiple imputation was used to impute missing dNCC assuming data were missing not at random.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to Week 48', 'description': 'dNCC is the directly quantified copper not bound to ceruloplasmin, obtained by inductively coupled plasma mass spectrometry after immunocapture and removal of ceruloplasmin. Baseline was defined as last non-missing value on or before first study drug administration. Least square (LS) mean and standard error (SE) was calculated using analysis of covariance (ANCOVA).', 'unitOfMeasure': 'micromoles (µmol)*hours (hr)/liter (L)', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set included all randomized participants who received at least 1 dose of randomized treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '89', 'groupId': 'OG000'}, {'value': '41', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Week 48', 'description': "An AE was any untoward medical occurrence in a participant administered the study drug and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as those AEs with onset after the first dose of randomized treatment or existing events that worsened in severity after the first dose of randomized treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants who received at least 1 dose of randomized treatment.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.7', 'spread': '2.75', 'groupId': 'OG000', 'lowerLimit': '2.75'}, {'value': '0.0', 'spread': '2.31', 'groupId': 'OG001', 'lowerLimit': '2.31'}, {'value': '-0.5', 'spread': '3.23', 'groupId': 'OG002', 'lowerLimit': '3.23'}, {'value': '-1.8', 'spread': '4.63', 'groupId': 'OG003', 'lowerLimit': '4.63'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': 'The UWDRS comprises 3 parts: UWDRS Part I (level of consciousness, item 1), UWDRS Part II (a patient-reported review of daily activity items \\[disability\\], items 2 to 11 \\[10 items in total\\]), and UWDRS Part III (a detailed neurological examination, items 12 to 34 \\[23 items in total\\]). The UWDRS Part II total score was calculated as the sum of Question 2 to Question 11 (each question has range 0 \\[none\\] to 4 \\[severe\\]). The UWDRS Part II total score ranges from 0 (no disability) to 40 (severe disability), with lower score indicating improvement in condition and a better outcome. Change from baseline was calculated as: postbaseline assessment value - baseline assessment value when both values were not missing.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in UWDRS Part III Total Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.24', 'spread': '7.458', 'groupId': 'OG000', 'lowerLimit': '7.458'}, {'value': '-1.59', 'spread': '6.188', 'groupId': 'OG001', 'lowerLimit': '6.188'}, {'value': '-2.06', 'spread': '9.843', 'groupId': 'OG002', 'lowerLimit': '9.843'}, {'value': '1.55', 'spread': '5.889', 'groupId': 'OG003', 'lowerLimit': '5.889'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': 'The UWDRS comprises 3 parts: UWDRS Part I (level of consciousness, item 1), UWDRS Part II (a patient-reported review of daily activity items \\[disability\\], items 2 to 11 \\[10 items in total\\]), and UWDRS Part III (a detailed neurological examination, items 12 to 34 \\[23 items in total\\]). The UWDRS Part I and III was assessed by a neurologist who was blinded to the treatment randomization. The UWDRS Part III total score was calculated as the sum of Question 12 to Question 34. The UWDRS Part III total score ranges from 0 (normal) to 175 (severe disease), with lower score indicating improvement in condition and a better outcome. Change from baseline was calculated as: postbaseline assessment value - baseline assessment value when both values were not missing.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.165', 'spread': '0.7620', 'groupId': 'OG000', 'lowerLimit': '0.7620'}, {'value': '-0.102', 'spread': '0.5467', 'groupId': 'OG001', 'lowerLimit': '0.5467'}, {'value': '-0.090', 'spread': '0.8464', 'groupId': 'OG002', 'lowerLimit': '0.8464'}, {'value': '0.227', 'spread': '0.4214', 'groupId': 'OG003', 'lowerLimit': '0.4214'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': 'UWDRS Part III Functional Subscale consists of speech, handwriting, arising from chair, and gait from UWDRS Part III. The standardized score of the first 3 items ranges from 0 (normal) to 10 (worst), and standardized transformed score of gait ranges from 0 (normal) to 10 (worst). The average of these scores was used to create the Part III Functional Subscale with a range of 0 (normal) - 10 (worst) with higher scores indicating more functional disability.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in UWDRS Part III Individual Items/Subscales (Speech, Handwriting, Arising From a Chair, and Gait) Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'title': 'Speech', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.50', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '0.35', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '0.52', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '0.54', 'groupId': 'OG003'}]}]}, {'title': 'Handwriting', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.48', 'groupId': 'OG001'}, {'value': '0.1', 'spread': '0.60', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '0.40', 'groupId': 'OG003'}]}]}, {'title': 'Arising from a chair', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.45', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.56', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '0.27', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '0.00', 'groupId': 'OG003'}]}]}, {'title': 'Gait', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '1.317', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '1.141', 'groupId': 'OG001'}, {'value': '-0.18', 'spread': '0.945', 'groupId': 'OG002'}, {'value': '0.23', 'spread': '0.754', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': 'UWDRS Part III individual items speech, handwriting, arising from chair, and gait are reported here. For speech (Question 12), original score ranges from 0 (normal) to 4 (unintelligible). For handwriting (Question 20), original score ranges from 0 (normal) to 4 (cannot hold a pen). For arising from chair (Question 27), original score ranges from 0 (normal) to 4 (unable to arise without help). For gait (Question 29), the original score (range: 0 \\[normal\\] to 10 \\[severe condition\\]) was calculated by summing subscores (0 \\[normal\\] to 4 \\[severe\\]) of Part A (Right and Left Leg dystonia), B (Ataxia), and C (Parkinsonism).', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified category."}, {'type': 'SECONDARY', 'title': 'Clinical Global Impression-Improvement Scale (CGI-I) Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.4', 'spread': '0.89', 'groupId': 'OG000', 'lowerLimit': '0.89'}, {'value': '3.8', 'spread': '0.80', 'groupId': 'OG001', 'lowerLimit': '0.80'}, {'value': '3.1', 'spread': '1.06', 'groupId': 'OG002', 'lowerLimit': '1.06'}, {'value': '3.2', 'spread': '1.34', 'groupId': 'OG003', 'lowerLimit': '1.34'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 48', 'description': "The CGI-I is a 7-point scale where the clinician assessed how much participant's illness improved or worsened relative to a Baseline state at the beginning of the intervention and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.79', 'groupId': 'OG000', 'lowerLimit': '0.79'}, {'value': '-0.1', 'spread': '0.73', 'groupId': 'OG001', 'lowerLimit': '0.73'}, {'value': '-0.6', 'spread': '1.11', 'groupId': 'OG002', 'lowerLimit': '1.11'}, {'value': '-0.5', 'spread': '1.21', 'groupId': 'OG003', 'lowerLimit': '1.21'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': "The CGI-S is a 7-point scale where the investigator rated severity of participant's illness at the time of assessment, relative to the investigator's past experience with participants who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of illness at time of rating as: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Model for End-Stage Liver Disease (MELD) Score at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '86', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '28', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.85', 'groupId': 'OG000', 'lowerLimit': '1.85'}, {'value': '0.1', 'spread': '1.32', 'groupId': 'OG001', 'lowerLimit': '1.32'}, {'value': '-0.7', 'spread': '1.61', 'groupId': 'OG002', 'lowerLimit': '1.61'}, {'value': '0.2', 'spread': '1.25', 'groupId': 'OG003', 'lowerLimit': '1.25'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': "The MELD score uses the participant's values for bilirubin, creatinine, and the international normalized ratio (INR). The initial MELD score (MELD\\[i\\]) is calculated according to the following formula: MELD(i) = 3.78\\*ln\\[serum bilirubin (mg/dL)\\] + 11.2\\*ln\\[INR\\] + 9.57\\*ln\\[serum creatinine (mg/dL)\\] + 6.43. Creatinine, bilirubin, and INR values less than 1.0 are set to 1.0 and creatinine values greater than 4.0 are set to 4.0 when calculating MELD(i). Additionally, creatinine, bilirubin, and INR are rounded to the 10th decimal place prior to performing the calculation. The initial MELD score is then rounded to the nearest integer. The MELD score ranges from 6 (least sick) - 40 (most sick), with higher values indicating more advanced disease.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Absolute Change From Baseline in Calculated Non-Ceruloplasmin Bound Copper (cNCC) or Calculated Non-Ceruloplasmin Bound Copper Corrected (cNCCcorrected) in Plasma at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}, {'value': '26', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.72', 'spread': '1.107', 'groupId': 'OG000', 'lowerLimit': '1.107'}, {'value': '0.64', 'spread': '2.769', 'groupId': 'OG001', 'lowerLimit': '2.769'}, {'value': '-1.95', 'spread': '1.536', 'groupId': 'OG002', 'lowerLimit': '1.536'}, {'value': '-1.51', 'spread': '2.361', 'groupId': 'OG003', 'lowerLimit': '2.361'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': 'cNCC = Plasma Total Copper (Cu) \\[micrograms (µg)/L\\]-(3.15\\*ceruloplasmin \\[milligrams (mg)/L\\])/63.5 \\[µg/µmol\\] For ALXN1840-treated participants, cNCC in plasma corrected for amount of Cu bound to ALXN1840 tripartite complex (TPC) cNCCcorrected = (√cNCC- 0.993)2√Mo, (Mo= molybdenum). In calculation of cNCC and cNCCcorrected following rules apply: - For plasma total Cu concentration \\<lower limit of quantification (LLOQ), cNCC was considered missing (LLOQ = 20 nanograms \\[ng\\]/mL); - Serum ceruloplasmin concentration values \\<LLOQ are set to 0 (LLOQ = 22.5 mg/L); - Plasma total Mo concentration values \\<LLOQ are set to 0 (LLOQ = 1 ng/L); - If cNCC calculation produces a negative result, cNCC was considered missing and cNCCcorrected was not derived; - cNCCcorrected was set to 0 when 0.993√Mo \\> √cNCC.', 'unitOfMeasure': 'µmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set: all randomized participants who received at least 1 dose of study drug. 'Overall number of participants analyzed'= participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in cNCC or cNCCcorrected in Plasma at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '60', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '26', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '-7.7', 'spread': '263.20', 'groupId': 'OG000', 'lowerLimit': '263.20'}, {'value': '104.6', 'spread': '292.11', 'groupId': 'OG001', 'lowerLimit': '292.11'}, {'value': '-64.0', 'spread': '42.88', 'groupId': 'OG002', 'lowerLimit': '42.88'}, {'value': '-44.3', 'spread': '68.82', 'groupId': 'OG003', 'lowerLimit': '68.82'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 48', 'description': 'cNCC \\[µmol/L\\] = Plasma Total Cu \\[µg/L\\]-(3.15\\*ceruloplasmin \\[mg/L\\])/63.5 \\[µg/µmol\\] For ALXN1840-treated participants, cNCC in plasma was corrected for amount of Cu bound to the ALXN1840 TPC using square root-based cNCC correction method: cNCCcorrected = (√cNCC- 0.993)2√Mo, where Mo = molybdenum. In calculation of cNCC and cNCCcorrected following rules apply: - For plasma total Cu concentration values \\<LLOQ, cNCC was considered missing (LLOQ = 20 ng/mL); - Serum ceruloplasmin concentration values \\<LLOQ are set to 0 (LLOQ = 22.5 mg/L); - Plasma total Mo concentration values \\<LLOQ are set to 0 (LLOQ = 1 ng/L); - In cases where cNCC calculation produces a negative result, cNCC was considered missing and cNCCcorrected was not derived; - cNCCcorrected was set to 0 when 0.993√Mo \\> √cNCC.', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Full analysis set included all randomized participants who received at least 1 dose of randomized treatment. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'cNCC/cNCCcorrected Responder at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'OG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'OG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}], 'classes': [{'categories': [{'measurements': [{'value': '101', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 48', 'description': 'cNCC/cNCCcorrected responder was defined as participants who achieved or maintained normalized cNCC/cNCCcorrected concentration (0.8-2.3 μmol) within (at or before) 48 weeks or reached a reduction of at least 25% in cNCC/cNCCcorrected within 48 weeks. Thus, a participant was considered a cNCC/cNCCcorrected responder if they met at least 1 of the following criteria: - Achieved normalized cNCC/cNCCcorrected concentration for 2 consecutive measurements within 48 weeks, for participants who had elevated cNCC concentrations at baseline; - Maintained normalized cNCC/cNCCcorrected concentration within 48 weeks, for participants who had normal cNCC concentrations at baseline; - Reached a reduction of at least 25% in cNCC/cNCCcorrected for 2 consecutive measurements within 48 weeks.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set included all randomized participants who received at least 1 dose of randomized treatment.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'FG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'FG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and continued to receive ALXN1840 for up to 60 months.'}, {'id': 'FG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received SoC therapy according to the local package label for up to 48 weeks in PEP. Participants who completed the 48-week PEP were offered the opportunity to participate in the OLE Period and received ALXN1840 for up to 60 months.'}, {'id': 'FG004', 'title': 'Cohort 1: WTX101-201- ALXN1840', 'description': 'Participants who received ALXN1840 during Study WTX101-201 (NCT02273596) continued to receive ALXN1840 for up to 60 months in the OLE period of this study.'}, {'id': 'FG005', 'title': 'Cohort 2: WTX101-201- ALXN1840', 'description': 'Participants who received ALXN1840 during Study WTX101-201 (NCT02273596) continued to receive ALXN1840 for up to 60 months in the OLE period of this study.'}], 'periods': [{'title': 'Primary Evaluation Period (48 Weeks)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '105'}, {'groupId': 'FG001', 'numSubjects': '56'}, {'groupId': 'FG002', 'numSubjects': '37'}, {'groupId': 'FG003', 'numSubjects': '16'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Received at Least 1 Dose of Study Drug', 'achievements': [{'groupId': 'FG000', 'numSubjects': '104'}, {'groupId': 'FG001', 'numSubjects': '56'}, {'groupId': 'FG002', 'numSubjects': '33'}, {'groupId': 'FG003', 'numSubjects': '14'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Completed PEP, Enter Extension', 'achievements': [{'groupId': 'FG000', 'numSubjects': '89'}, {'groupId': 'FG001', 'numSubjects': '49'}, {'groupId': 'FG002', 'numSubjects': '28'}, {'groupId': 'FG003', 'numSubjects': '12'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Completed PEP, Not Into Extension', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '93'}, {'groupId': 'FG001', 'numSubjects': '52'}, {'groupId': 'FG002', 'numSubjects': '29'}, {'groupId': 'FG003', 'numSubjects': '13'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Protocol Deviation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Randomized but not treated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': 'Extension Period (Up to 60 Months)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '89'}, {'groupId': 'FG001', 'numSubjects': '49'}, {'groupId': 'FG002', 'numSubjects': '28'}, {'groupId': 'FG003', 'numSubjects': '12'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '11'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '89'}, {'groupId': 'FG001', 'numSubjects': '49'}, {'groupId': 'FG002', 'numSubjects': '28'}, {'groupId': 'FG003', 'numSubjects': '12'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '10'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Protocol Deviation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Study Terminated by Sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '66'}, {'groupId': 'FG001', 'numSubjects': '32'}, {'groupId': 'FG002', 'numSubjects': '21'}, {'groupId': 'FG003', 'numSubjects': '10'}, {'groupId': 'FG004', 'numSubjects': '7'}, {'groupId': 'FG005', 'numSubjects': '8'}]}, {'type': 'Other than specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'The study consisted of 2 periods: Primary Evaluation Period (PEP) and Open-label Extension (OLE) Period. Participants who completed the 48-week PEP were offered the opportunity to continue treatment in an up to 60-month Extension. A total of 214 participants were randomized; 207 participants were treated in the PEP.', 'preAssignmentDetails': 'Participants were randomized, stratified by cohort, in a 2:1 ratio to treatment with ALXN1840 or continued treatment with Standard of Care (SoC). Two cohorts were defined. Cohort 1: participants previously treated with SoC for \\>28 days; Cohort 2: participants who were treatment naïve or previously treated with SoC for ≤28 days. Participants who completed participation in Study WTX101-201 (NCT02273596) were offered the opportunity to participate in the Study WTX101-301 OLE Period.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'BG000'}, {'value': '56', 'groupId': 'BG001'}, {'value': '33', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '11', 'groupId': 'BG005'}, {'value': '226', 'groupId': 'BG006'}]}], 'groups': [{'id': 'BG000', 'title': 'Cohort 1: ALXN1840', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) received titrated doses of ALXN1840 orally for up to 48 weeks.'}, {'id': 'BG001', 'title': 'Cohort 1: SoC Therapy', 'description': 'Participants in Cohort 1 (who received SoC therapy, that is, chelation therapy with penicillamine or trientine, zinc therapy, or a combination of both chelation and zinc therapy for \\>28 days) continued to receive SoC therapy for up to 48 weeks according to the local package label.'}, {'id': 'BG002', 'title': 'Cohort 2: ALXN1840', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received titrated doses of ALXN1840 orally for up to 48 weeks.'}, {'id': 'BG003', 'title': 'Cohort 2: SoC Therapy', 'description': 'Participants in Cohort 2 (who were treatment naïve or who received SoC therapy for ≤28 days) received/continued to receive SoC therapy for up to 48 weeks according to the local package label.'}, {'id': 'BG004', 'title': 'Cohort 1: WTX101-201- ALXN1840', 'description': 'Participants who received ALXN1840 during Study WTX101-201 (NCT02273596) continued to receive ALXN1840 for up to 60 months.'}, {'id': 'BG005', 'title': 'Cohort 2: WTX101-201- ALXN1840', 'description': 'Participants who received ALXN1840 during Study WTX101-201 (NCT02273596) continued to receive ALXN1840 for up to 60 months.'}, {'id': 'BG006', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'categories': [{'title': '≥12 years - <18 years', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '18', 'groupId': 'BG006'}]}, {'title': '≥18 years - <65 years', 'measurements': [{'value': '92', 'groupId': 'BG000'}, {'value': '50', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '11', 'groupId': 'BG005'}, {'value': '203', 'groupId': 'BG006'}]}, {'title': '≥65 years', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '46', 'groupId': 'BG000'}, {'value': '30', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}, {'value': '98', 'groupId': 'BG006'}]}, {'title': 'Male', 'measurements': [{'value': '58', 'groupId': 'BG000'}, {'value': '26', 'groupId': 'BG001'}, {'value': '24', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '128', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Race', 'categories': [{'title': 'Asian', 'measurements': [{'value': '19', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '39', 'groupId': 'BG006'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}, {'title': 'White', 'measurements': [{'value': '80', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '176', 'groupId': 'BG006'}]}, {'title': 'Other', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}]}, {'title': 'Unknown', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}]}, {'title': 'Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '7', 'groupId': 'BG006'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '101', 'groupId': 'BG000'}, {'value': '54', 'groupId': 'BG001'}, {'value': '32', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '11', 'groupId': 'BG005'}, {'value': '216', 'groupId': 'BG006'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The Full Analysis Set included all randomized participants who received at least 1 dose of randomized treatment.\n\nThe Extension Analysis Set included all participants who entered the Extension Period and received at least 1 dose of ALXN1840 in the Extension Period. This included the participants who rolled over from Study WTX101-201.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-04-27', 'size': 1438080, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-09-13T14:56', 'hasProtocol': True}, {'date': '2021-08-06', 'size': 838987, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-09-13T14:56', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR'], 'maskingDescription': 'This study is rater-blinded for the Unified Wilson Disease Rating Scale (UWDRS) assessment only.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 214}}, 'statusModule': {'whyStopped': 'Sponsor decision to terminate the program', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2018-02-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'dispFirstSubmitDate': '2022-01-20', 'completionDateStruct': {'date': '2023-06-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-06-14', 'studyFirstSubmitDate': '2017-12-19', 'dispFirstSubmitQcDate': '2022-01-20', 'resultsFirstSubmitDate': '2023-09-13', 'studyFirstSubmitQcDate': '2018-01-10', 'dispFirstPostDateStruct': {'date': '2022-01-25', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2024-06-17', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-09-13', 'studyFirstPostDateStruct': {'date': '2018-01-18', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-10-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-06-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W)', 'timeFrame': 'Baseline to Week 48', 'description': 'dNCC is the directly quantified copper not bound to ceruloplasmin, obtained by inductively coupled plasma mass spectrometry after immunocapture and removal of ceruloplasmin. Baseline was defined as last non-missing value on or before first study drug administration. Least square (LS) mean and standard error (SE) was calculated using analysis of covariance (ANCOVA).'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Baseline up to Week 48', 'description': "An AE was any untoward medical occurrence in a participant administered the study drug and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as those AEs with onset after the first dose of randomized treatment or existing events that worsened in severity after the first dose of randomized treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section."}, {'measure': 'Change From Baseline in the Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': 'The UWDRS comprises 3 parts: UWDRS Part I (level of consciousness, item 1), UWDRS Part II (a patient-reported review of daily activity items \\[disability\\], items 2 to 11 \\[10 items in total\\]), and UWDRS Part III (a detailed neurological examination, items 12 to 34 \\[23 items in total\\]). The UWDRS Part II total score was calculated as the sum of Question 2 to Question 11 (each question has range 0 \\[none\\] to 4 \\[severe\\]). The UWDRS Part II total score ranges from 0 (no disability) to 40 (severe disability), with lower score indicating improvement in condition and a better outcome. Change from baseline was calculated as: postbaseline assessment value - baseline assessment value when both values were not missing.'}, {'measure': 'Change From Baseline in UWDRS Part III Total Score at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': 'The UWDRS comprises 3 parts: UWDRS Part I (level of consciousness, item 1), UWDRS Part II (a patient-reported review of daily activity items \\[disability\\], items 2 to 11 \\[10 items in total\\]), and UWDRS Part III (a detailed neurological examination, items 12 to 34 \\[23 items in total\\]). The UWDRS Part I and III was assessed by a neurologist who was blinded to the treatment randomization. The UWDRS Part III total score was calculated as the sum of Question 12 to Question 34. The UWDRS Part III total score ranges from 0 (normal) to 175 (severe disease), with lower score indicating improvement in condition and a better outcome. Change from baseline was calculated as: postbaseline assessment value - baseline assessment value when both values were not missing.'}, {'measure': 'Change From Baseline in UWDRS Part III Functional Subscale Score at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': 'UWDRS Part III Functional Subscale consists of speech, handwriting, arising from chair, and gait from UWDRS Part III. The standardized score of the first 3 items ranges from 0 (normal) to 10 (worst), and standardized transformed score of gait ranges from 0 (normal) to 10 (worst). The average of these scores was used to create the Part III Functional Subscale with a range of 0 (normal) - 10 (worst) with higher scores indicating more functional disability.'}, {'measure': 'Change From Baseline in UWDRS Part III Individual Items/Subscales (Speech, Handwriting, Arising From a Chair, and Gait) Score at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': 'UWDRS Part III individual items speech, handwriting, arising from chair, and gait are reported here. For speech (Question 12), original score ranges from 0 (normal) to 4 (unintelligible). For handwriting (Question 20), original score ranges from 0 (normal) to 4 (cannot hold a pen). For arising from chair (Question 27), original score ranges from 0 (normal) to 4 (unable to arise without help). For gait (Question 29), the original score (range: 0 \\[normal\\] to 10 \\[severe condition\\]) was calculated by summing subscores (0 \\[normal\\] to 4 \\[severe\\]) of Part A (Right and Left Leg dystonia), B (Ataxia), and C (Parkinsonism).'}, {'measure': 'Clinical Global Impression-Improvement Scale (CGI-I) Score at Week 48', 'timeFrame': 'Week 48', 'description': "The CGI-I is a 7-point scale where the clinician assessed how much participant's illness improved or worsened relative to a Baseline state at the beginning of the intervention and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse."}, {'measure': 'Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) Score at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': "The CGI-S is a 7-point scale where the investigator rated severity of participant's illness at the time of assessment, relative to the investigator's past experience with participants who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of illness at time of rating as: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill."}, {'measure': 'Change From Baseline in Model for End-Stage Liver Disease (MELD) Score at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': "The MELD score uses the participant's values for bilirubin, creatinine, and the international normalized ratio (INR). The initial MELD score (MELD\\[i\\]) is calculated according to the following formula: MELD(i) = 3.78\\*ln\\[serum bilirubin (mg/dL)\\] + 11.2\\*ln\\[INR\\] + 9.57\\*ln\\[serum creatinine (mg/dL)\\] + 6.43. Creatinine, bilirubin, and INR values less than 1.0 are set to 1.0 and creatinine values greater than 4.0 are set to 4.0 when calculating MELD(i). Additionally, creatinine, bilirubin, and INR are rounded to the 10th decimal place prior to performing the calculation. The initial MELD score is then rounded to the nearest integer. The MELD score ranges from 6 (least sick) - 40 (most sick), with higher values indicating more advanced disease."}, {'measure': 'Absolute Change From Baseline in Calculated Non-Ceruloplasmin Bound Copper (cNCC) or Calculated Non-Ceruloplasmin Bound Copper Corrected (cNCCcorrected) in Plasma at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': 'cNCC = Plasma Total Copper (Cu) \\[micrograms (µg)/L\\]-(3.15\\*ceruloplasmin \\[milligrams (mg)/L\\])/63.5 \\[µg/µmol\\] For ALXN1840-treated participants, cNCC in plasma corrected for amount of Cu bound to ALXN1840 tripartite complex (TPC) cNCCcorrected = (√cNCC- 0.993)2√Mo, (Mo= molybdenum). In calculation of cNCC and cNCCcorrected following rules apply: - For plasma total Cu concentration \\<lower limit of quantification (LLOQ), cNCC was considered missing (LLOQ = 20 nanograms \\[ng\\]/mL); - Serum ceruloplasmin concentration values \\<LLOQ are set to 0 (LLOQ = 22.5 mg/L); - Plasma total Mo concentration values \\<LLOQ are set to 0 (LLOQ = 1 ng/L); - If cNCC calculation produces a negative result, cNCC was considered missing and cNCCcorrected was not derived; - cNCCcorrected was set to 0 when 0.993√Mo \\> √cNCC.'}, {'measure': 'Percent Change From Baseline in cNCC or cNCCcorrected in Plasma at Week 48', 'timeFrame': 'Baseline, Week 48', 'description': 'cNCC \\[µmol/L\\] = Plasma Total Cu \\[µg/L\\]-(3.15\\*ceruloplasmin \\[mg/L\\])/63.5 \\[µg/µmol\\] For ALXN1840-treated participants, cNCC in plasma was corrected for amount of Cu bound to the ALXN1840 TPC using square root-based cNCC correction method: cNCCcorrected = (√cNCC- 0.993)2√Mo, where Mo = molybdenum. In calculation of cNCC and cNCCcorrected following rules apply: - For plasma total Cu concentration values \\<LLOQ, cNCC was considered missing (LLOQ = 20 ng/mL); - Serum ceruloplasmin concentration values \\<LLOQ are set to 0 (LLOQ = 22.5 mg/L); - Plasma total Mo concentration values \\<LLOQ are set to 0 (LLOQ = 1 ng/L); - In cases where cNCC calculation produces a negative result, cNCC was considered missing and cNCCcorrected was not derived; - cNCCcorrected was set to 0 when 0.993√Mo \\> √cNCC.'}, {'measure': 'cNCC/cNCCcorrected Responder at Week 48', 'timeFrame': 'Week 48', 'description': 'cNCC/cNCCcorrected responder was defined as participants who achieved or maintained normalized cNCC/cNCCcorrected concentration (0.8-2.3 μmol) within (at or before) 48 weeks or reached a reduction of at least 25% in cNCC/cNCCcorrected within 48 weeks. Thus, a participant was considered a cNCC/cNCCcorrected responder if they met at least 1 of the following criteria: - Achieved normalized cNCC/cNCCcorrected concentration for 2 consecutive measurements within 48 weeks, for participants who had elevated cNCC concentrations at baseline; - Maintained normalized cNCC/cNCCcorrected concentration within 48 weeks, for participants who had normal cNCC concentrations at baseline; - Reached a reduction of at least 25% in cNCC/cNCCcorrected for 2 consecutive measurements within 48 weeks.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Wilson Disease', 'ALXN1840', 'Copper'], 'conditions': ['Wilson Disease']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=WTX101-301&attachmentIdentifier=7e63eb7b-ff32-4ef3-ba97-94d6dd3d86cd&fileName=wtx101-301-CSR_Synopsis_redacted.pdf&versionIdentifier=', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optional 60-month Extension Period.', 'detailedDescription': 'The study consists of 2 cohorts. Cohort 1: Participants who have received SoC therapy for \\> 28 days and Cohort 2: Participants who are treatment-naïve or who have received SoC therapy for ≤ 28 days.\n\nAll enrolled participants were randomized by cohort in a 2:1 ratio to treatment with ALXN1840 or SoC (either as continued therapy in Cohort 1 or as continued or initial therapy in Cohort 2).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key Inclusion Criteria:\n\n* Established diagnosis of WD by Leipzig-Score ≥ 4\n* Female participants of childbearing potential, if heterosexually active, must be willing to follow protocol-specified guidance for highly effective contraception starting at least 6 weeks before the Day 1 visit and continuing through 28 days after the last dose of either ALXN1840 or SoC\n* Male participants, if heterosexually active, must be willing to follow protocol-specified guidance for highly effective contraception beginning at Day 1 visit and continuing through 90 days after last dose of either ALXN1840 or SoC\n\nKey Exclusion Criteria:\n\n* Decompensated hepatic cirrhosis\n* MELD score \\> 13\n* Modified Nazer score \\> 7\n* Clinically significant gastrointestinal bleed within past 3 months\n* Alanine aminotransferase \\> 2 X upper limit of normal (ULN) for participants treated for \\> 28 days with WD therapy (Cohort 1)\n* Alanine aminotransferase \\> 5 X ULN for treatment-naïve participants or participants who have been treated for ≤ 28 days (Cohort 2)\n* Marked neurological disease requiring either nasogastric feeding or intensive inpatient medical care\n* Hemoglobin \\< 9 grams/deciliter\n* History of seizure activity within 6 months prior to informed consent\n* Pregnant (or women who are planning to become pregnant) or breastfeeding women\n* Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus or seropositivity for human immunodeficiency virus (HIV)\n* Previous treatment with tetrathiomolybdate\n* Participants with end-stage renal disease on dialysis (chronic kidney disease stage 5) or creatinine clearance \\< 30 milliliter/minute'}, 'identificationModule': {'nctId': 'NCT03403205', 'briefTitle': 'Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease', 'organization': {'class': 'INDUSTRY', 'fullName': 'Alexion Pharmaceuticals, Inc.'}, 'officialTitle': 'A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months', 'orgStudyIdInfo': {'id': 'WTX101-301'}, 'secondaryIdInfos': [{'id': '2017-004135-36', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ALXN1840', 'description': 'ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.\n\nParticipants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.', 'interventionNames': ['Drug: ALXN1840']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Standard of Care (SoC) Medication', 'description': 'SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.', 'interventionNames': ['Drug: SoC Therapy']}], 'interventions': [{'name': 'ALXN1840', 'type': 'DRUG', 'otherNames': ['Formerly named WTX101', 'Tiomolibdic acid', 'Tiomolibdate choline', 'Bis-choline tetrathiomolybdate'], 'description': 'ALXN1840 administered orally in 15 mg tablets', 'armGroupLabels': ['ALXN1840']}, {'name': 'SoC Therapy', 'type': 'DRUG', 'description': 'Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.', 'armGroupLabels': ['Standard of Care (SoC) Medication']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '98105', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '5000', 'city': 'Adelaide', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '2139', 'city': 'Concord', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -33.84722, 'lon': 151.10381}}, {'zip': '3050', 'city': 'Parkville', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -37.78333, 'lon': 144.95}}, {'zip': 'VIC 3052', 'city': 'Parkville', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -37.78333, 'lon': 144.95}}, {'zip': '8036', 'city': 'Graz', 'country': 'Austria', 'facility': 'Research Site', 'geoPoint': {'lat': 47.06733, 'lon': 15.44197}}, {'zip': '6020', 'city': 'Innsbruck', 'country': 'Austria', 'facility': 'Research Site', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Research Site', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': 'M5G 2C4', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '128 08', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '8200', 'city': 'Århus N', 'country': 'Denmark', 'facility': 'Research Site'}, {'zip': '69667', 'city': 'Bron', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 45.73865, 'lon': 4.91303}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '20099', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '69120, DE', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '852', 'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Research Site', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'zip': '1083', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '9112001', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Research Site', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '5265601', 'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Research Site', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '266-0007', 'city': 'Chiba', 'country': 'Japan', 'facility': 'Research Site', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'zip': '860-8556', 'city': 'Kumamoto', 'country': 'Japan', 'facility': 'Research Site', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'zip': '830-0011', 'city': 'Kurume-shi', 'country': 'Japan', 'facility': 'Research Site'}, {'zip': '790-0024', 'city': 'Matsuyama', 'country': 'Japan', 'facility': 'Research Site', 'geoPoint': {'lat': 33.83916, 'lon': 132.76574}}, {'zip': '153-8515', 'city': 'Meguro-ku', 'country': 'Japan', 'facility': 'Research Site'}, {'zip': '063-0005', 'city': 'Sapporo', 'country': 'Japan', 'facility': 'Research Site', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '569-8686', 'city': 'Takatsuki-shi', 'country': 'Japan', 'facility': 'Research Site'}, {'zip': '230-8765', 'city': 'Yokohama', 'country': 'Japan', 'facility': 'Research Site', 'geoPoint': {'lat': 35.43333, 'lon': 139.65}}, {'zip': '1010', 'city': 'Grafton', 'country': 'New Zealand', 'facility': 'Research Site', 'geoPoint': {'lat': -36.86029, 'lon': 174.76566}}, {'zip': '02-957', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '04-730', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '115446', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '117292', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '119021', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '603005', 'city': 'Nizhny Novgorod', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 56.32867, 'lon': 44.00205}}, {'zip': '194017', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Research Site', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '169608', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'Research Site', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '41944', 'city': 'Daegu', 'country': 'South Korea', 'facility': 'Research Site', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '29011', 'city': 'Málaga', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '08208', 'city': 'Sabadell', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'zip': '10002', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Research Site', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333', 'city': 'Taoyuan', 'country': 'Taiwan', 'facility': 'Research Site', 'geoPoint': {'lat': 24.99368, 'lon': 121.29696}}, {'zip': '06230', 'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Research Site', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '34010', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Research Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34093', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Research Site', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '35100', 'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Research Site', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': 'B15 2WB', 'city': 'Edgbaston', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 52.4623, 'lon': -1.92115}}, {'zip': 'GU2 7WG', 'city': 'Guildford', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}, {'zip': 'SE5 9RS', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Eugene S. Swenson, M.D., Ph.D.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Alexion Pharmaceuticals, Inc.'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.', 'ipdSharing': 'YES', 'description': 'Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.\n\nAll request will be evaluated as per the AZ disclosure commitment:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.', 'accessCriteria': 'When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Alexion Pharmaceuticals, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}